Celularity Inc. raised “roughly in the $50 million range” by way of its series A round to boost cell and tissue regenerative therapies in cancer and other disorders, said Sorrento Therapeutics Inc. CEO Henry Ji, whose company is one of three involved in what amounts to a new business model. “Basically, the whole cell-therapy division of Celgene is coming back together into Celularity” as the end result, he told BioWorld.